What's new in the antibiotic pipeline
Related Experiment Video
Updated: Oct 19, 2026

Antibiotic Dereplication Using the Antibiotic Resistance Platform
Published on: October 17, 2019
V J Lee1, G H Miller, M Yagisawa
1Microcide Pharmaceuticals Inc. 850 Maude Avenue, Mountain View, CA 94043, USA. mailto:vingjlee@microcide.com.
Abstract:
Many advances have recently been made in the development of chemotherapeutic agents for bacterial infections. As a consequence of problematic antimicrobial-resistant bacteria, research is now directed towards narrow-spectrum agents rather than broad-spectrum agents. Further, orally active agents have always been desirable, but today's cost-saving environment, in line with a desire to minimize treatment costs, values reduced administration costs and keeping patients out of the hospital. There has been a recent increase in research into orally active antibacterial agents, such as carbapenems and cephalosporins, and non-glycopeptide natural products.
More Related Videos
05:57Fission Yeast as a Platform for Antibacterial Drug Screens Targeting Bacterial Cytoskeleton Proteins
Published on: April 26, 2024
09:17A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
Published on: January 2, 2017
Related Concept Videos
Production of Antibiotics
Clinical Significance of Antibiotic Resistance
Antibiotic Selection
Mechanism of Antibiotic Resistance in MRSA
Development of Antibiotic Resistance
Inhibitors of Gram-positive Cell Wall Synthesis